摘要
目的观察改良逍遥散联合氟西汀对2型糖尿病并发抑郁患者血糖的影响。方法选取2013年2月~2014年6月期间温州市中医院内分泌科诊断的2型糖尿病病发抑郁的患者86例,采随机数字表法分为观察组及对照组,每组各43例,观察组在对照组氟西汀治疗基础上加用改良逍遥散治疗,对照组患者给予单独应用氟西汀常规治疗,记录并分析治疗后2组餐后2小时血糖（2 h PG）、糖化血红蛋白（Hb A1c）、焦虑自评量表（SAS）、抑郁自评量表（SDS）和糖尿病生活质量特异性量表（DSQL）状况。结果观察组患者治疗后2 h PG、Hb A1c分别为（8.05±0.46、7.04±0.23）mmol/L,均优于对照组（9.45±0.55、7.87±0.30）mmol/L（P〈0.05）;观察组患者治疗后SAS及SDS得分分别为（42.05±2.01、39.16±2.15）分,均优于对照组（52.16±2.25、48.02±2.51）分（P〈0.05）;观察组患者治疗后DSQL得分为（56.49±4.17）分,优于对照组（69.01±5.24）分（P〈0.05）。结论改良逍遥散联合氟西汀对2型糖尿病病发抑郁患者血糖的疗效肯定、确切,与单独应用氟西汀治疗相比能有效改善糖尿病病发抑郁患者症状,值得临床进一步研究和应用。
Objective To analyze effects of improved Xiaoyaosan combine with fluoxetine on blood glucose of type 2 diabetes patients with depression symptoms. Methods 86 patients diagnosed with type 2 diabetes with depression from February 2013 to June 2014,prospective study was randomized into two groups and 43 cases in control group,43 cases in observation group,control group were treated with fluoxetine alone conventional treatment,after treatment,both groups were recorded and analyzed 2-hour postprandial blood glucose（ 2h PG）,glycated hemoglobin（ Hb A1c）,anxiety Rating scale（ SAS）,self-rating depression scale（ SDS） and the quality of life of diabetes-specific scale（ DSQL） status. Results The patients in obseruation group after treatment 2h PG,Hb A1 c respectively（ 8. 05 ± 0. 46,7. 04 ± 0. 23） mmol / L,was superior to control group（ 9. 45 ± 0. 55,7. 87 ±0. 30） mmol / L,and the difference was significant（ P〈0. 05）; observation group patients SAS and SDS scores were（ 42. 05 ± 2. 01,39. 16 ± 2. 15）points,was superior to control group（ 52. 16 ± 2. 25,48. 02 ± 2. 51） points,and the difference was significant（ P〈0. 05）; observed in patients after treatment DSQL score of（ 56. 49 ± 4. 17） points better than control group（ 69. 0 ± 5. 24） points,and the difference was significant（ P〈0. 05）.Conclusion Effect of modified Xiaoyaosan combined with fluoxetine in type 2 diabetes patients with depression symptoms is definite,compares with fluoxetine alone therapy can effectively improve diabetes onset depressive symptoms and it is worthy of further research and application.
出处
《中国生化药物杂志》
CAS
2016年第3期110-112,共3页
Chinese Journal of Biochemical Pharmaceutics
基金
温州市科技局课题(Y20140488)
关键词
改良逍遥散
氟西汀
2型糖尿病
抑郁
modified Xiaoyaosan
fluoxetine
type 2 diabetes
depression
